Abstract: Remedies for dry eye and diseases associated with dry eye which contain as the active ingredient peptides represented by the general formula (I): H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-X1-Gln-X2-Ala-Val-X3-X4-Tyr-Leu-X5-X6(SEQ ID NOS: 26-36) ??(I) wherein X1, X3 and X4 represent Lys or Arg, respectively; X2 represents Met, Leu or nLeu; X5 represents a chemical bond, Asn, Asn-Ser, Asn-Ser-Ile, Asn-Ser-Ile-Leu(SEQ ID NO: 37) or Asn-Ser-Ile-Leu-Asn-X7(SEQ ID NOS: 38-43) (wherein X7 represents a chemical bond, Gly, etc.); and X6 represents —OH or —NH2, or pharmaceutically acceptable salts thereof:.

Abstract: Remedies for dry eye and diseases associated with dry eye which contain as the active ingredient peptides represented by the general formula (I):

Abstract: The present invention provides a therapeutic and/or prophylactic agent against conformational diseases. An object of the present invention is to provide a therapeutic and/or prophylactic agent against conformational diseases, which comprise, as an active ingredient, a neuropeptide or a pharmacologically acceptable salt thereof having neuroprotective action.

Abstract: The present invention provides a powder formulation that can be obtained by mixing fine particles containing powdery medicament and excipient and having an average particle diameter of not more than 20 &mgr;m with a carrier having an aerodynamically acceptable particle diameter. The formulation can be easily handled pharmaceutically, and can retain a constant medicament content because of improved dispersibility and flowability.

Abstract: This invention relates to a method for producing an LH-RH derivative, characterized in that a peptide fragment shown by general formula (1): pGlu-His-Trp-OR1 (where R1 denotes a lower alkyl) and a peptide fragment shown by general formula (2): H-Ser-Tyr-X-Leu-Arg-Pro-Y (where X denotes an amino acid selected from the group consisting of D-amino acids such as D-Leu, D-Ser(But), D-Trp, and (2-napthyl)-D-Ala, and Gly, and Y denotes Gly-NH2, Azgly(Azaglycine)-NH2 or NHR2 (R2 is lower alkyl)) are allowed to react in the presence of chymotrypsin or a chymotrypsin-like enzymes, to produce the LH-RH derivative shown by general formula (3): pGlu-His-Trp-Ser-Tyr-X-Leu-Arg-Pro-Y (where X and Y are as defined above). Since the method does not accompany a side reaction such as racemization, it enables simple separation and purification of LH-RH derivatives. Moreover the method enables to provide high yields, as well as recovery and recycling of unreacted peptide fragments, therefore it is valuable in industrial use.

Abstract: The present invention relates to a peptide represented by the general formula (1): ##STR1## wherein A is Ala or Gly; B is Ile or Val; C is Asn or Ser; D is Thr or Ser; E is Leu or Tyr; each of F, I and J is Lys or Arg, and at least one of F, I and J is Arg; G is Met, Leu or Nle; K is Asn or Ala; L is Ser or Ala; M is Ile or Val; and N is --NH.sub.2 or Asn--NH.sub.2, excluding the combination where A is Ala, B is Val, C is Asn, D is Thr, E is Leu, K is Asn, L is Ser, M is Ile, and N is Asn--NH.sub.2, and pharmaceutically acceptable salts thereof, as well as to a bronchus-expanding agent or a blood-flow-improving agent comprising said peptide or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: Novel peptides represented by the following formulaR.sub.1 --A--B--C--D--Trp--Met--Y (1)wherein; R.sub.1 denotes pGlu, X--R.sub.2 --CO--, X being carboxyl or amino and R.sub.2 being lower alkylene of 1-6 carbon atoms, or ##STR1## A denotes Asp, Ala, or merely a chemical bond; B denotes Tyr(SO.sub.3 H) or Phe(NHSO.sub.3 H); C denotes Met or merely a chemical bond; D denotes Gly, D--Ala, or D--Trp; and Y denotes NH.sub.2, Asp--NH.sub.2, or Asp--Phe--NH.sub.2 ; with the proviso that Y is NH.sub.2 or Asp--NH.sub.2 when R.sub.1 is pGlu, HOOC--R.sub.2 --CO--, or ##STR2## B is Tyr(SO.sub.3 H), C is Met, and D is Gly, and pharmacologically acceptable salts thereof.